Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 data suggesting its experimental hypertension treatment lorundrostat may provide benefits for patients with chronic kidney disease, a finding that …
Mineralys Reports Kidney Disease Data Ahead of FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) received U.S. Food and Drug Administration acceptance for its application seeking approval of lorundrostat for uncontrolled or resistant hypertension, moving the company …
Mineralys Advances Hypertension Drug Toward FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted stock options and restricted stock unit awards to two newly hired non-executive employees under its employment inducement plan.
Mineralys Therapeutics (Nasdaq: MLYS) Grants Equity Awards to New Hires Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will report financial results for the first quarter ended March 31 on Wednesday, May 6, after market close.
Mineralys to Report First-Quarter Results on May 6 Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) said it granted stock options and restricted stock units to a new non-executive employee on March 16 as an inducement to join …
Mineralys Grants Inducement Equity Awards to New Employee Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported its fourth-quarter and full-year 2025 financial results and said the U.S. Food and Drug Administration has accepted its new drug application …
Mineralys Reports 2025 Results, Advances Hypertension Drug Review Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) announced that its board compensation committee granted inducement stock option and restricted stock unit awards to two new non-executive employees on February …
Mineralys Therapeutics Grants Inducement Equity Awards to Two New Employees Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) said this week it is approaching a pivotal stretch of clinical and regulatory milestones for lorundrostat, its lead drug candidate for difficult-to-treat …
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) said its Phase 3 Launch-HTN clinical trial evaluating lorundrostat was selected by JAMA editors as one of the most impactful medical studies …
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted an inducement stock option covering 146,000 shares to a newly hired non-executive employee, the company said following a November 24 action …
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances Read More